Krystal Biotech, Inc. (NASDAQ:KRYS) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Yahoo FinanceDec 23 19:40

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks Dec 19 23:30

BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $196

Futu NewsDec 19 18:33 · Ratings

Promising Clinical Data and Platform Potential Drive Buy Rating for Krystal Biotech

TipRanksDec 19 18:26 · Ratings

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

BenzingaDec 19 04:10

Krystal Biotech Says Initial Results From Kyanite-1 Trial Show 'Early Evidence' of Monotherapy Activity

MT NewswiresDec 18 22:23